个体化治疗根除幽门螺杆菌感染的成本-效果分析  

Cost-effectiveness analysis of tailored therapy for helicobacter pylori eradication

作　　者：谢珍国[1] 杜彪[1] 

机构地区：[1]重庆三峡中心医院药学部,重庆404000

出　　处：《中国药物经济学》2017年第10期22-26,共5页China Journal of Pharmaceutical Economics

摘　　要：目的对个体化方案、铋剂四联方案根除幽门螺杆菌感染进行药物经济学评价。方法基于1项随机、对照、双盲临床试验,构建决策树模型,比较个体化方案、铋剂四联方案与个体化补救方案的成本-效果和增量成本效果,并进行敏感性分析。结果个体化治疗组、铋剂四联组、个体化补救组成本-效果比(C/E)分别为989.96、299.24和515.85;个体化补救组相对于铋剂四联组的增量成本效果比为11 725.23。结论个体化方案作为一线方案不具有成本-效果,作为补救方案具有成本-效果。Objective To evaluate the pharmacoeconomic effectiveness of tailor therapy for helicobacter pylori eradication.Methods Based on a randomized,controlled,double-blind clinical trial,We constructed a decision tree model to analyze the cost-effectiveness and incremental cost-effectiveness of tailor therapy,triple therapy plus bismuth therapy and tailor remedial therapy for helicobacter pylori eradication,and sensitivity analysis was carried out.Results The cost-effectiveness ratios of tailor therapy,triple therapy plus bismuth therapy and tailor remedial therapy were 989.96 yuan,299.24 yuan and 515.85 yuan.The incremental cost-effectiveness ratio of tailor remedial therapy relative to Triple therapy plus bismuth therapy was 11725.23 yuan.Conclusion The tailor therapy have cost-effectiveness as a remedy,but are not available as first-line treatment protocols.

关 键 词：个体化方案 幽门螺杆菌 成本-效果分析 决策树模型 

分 类 号：R573.32[医药卫生—消化系统]